Events

Upcoming Events

2018 Gastrointestinal Cancers Symposium

January 18-20, 2018 — San Francisco, CA

Past Events

ESMO Immuno Oncology Congress 2017

December 9, 2017, 18:00 - 19:00 CEST — Geneva, Switzerland

Martin Oft, M.D., Vice President of Pre-Clinical and Clinical Development: PEGylated human IL-10 (AM0010) in combination with an anti-PD-1 in advanced NSCLC (Invited Discussant Session 18:34 - 18:54 CEST, Speaker: Alessandra Curioni)

December 8, 2017, 8:30 - 8:45 CEST — Geneva, Switzerland

Aung Naing, MD, FACP, Associate Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX: Efficacy of PEGylated human IL-10 (AM0010) in combination with anti-PD-1 blockade in patients (pts) with metastatic renal cell carcinoma (mRCC): A phase 1b trial

ESMO World Congress on Gastrointestinal Cancer

June 28, 2017, 17:30 - 18:00 CEST — Barcelona, Spain

Jeffrey R. Infante, M.D., Director, Drug Development Program, Principal Investigator, Sarah Cannon Research Institute: Immunologic and Objective Tumor Responses to PEGylated Human IL-10 (AM0010) with 5- FU/LV and Oxaliplatin (FOLFOX) in Metastatic Pancreatic Adenocarcinoma (PDAC)

Jefferies 2017 Global Healthcare Conference

June 8, 2017, 10:00 AM - 10:30 AM EDT — New York, NY

Click here for webcast

ASCO Annual Meeting

June 2-6, 2017 — Chicago, Illinois

12th European International Kidney Cancer Symposium

April 21-22, 2017 — Munich, Germany

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

February 23-25, 2017 — Orlando, FL

GTCbio ImmunoTX Summit

February 6-7, 2017 — San Diego, CA

2017 Gastrointestinal Cancers Symposium

January 19-21, 2017 — San Francisco, CA

SITC 2016 (Society for Immunotherapy Cancer)

November 9-13, 2016 — National Harbor, MD

ESMO 2016 Congress

October 7-11, 2016 — Copenhagen, Denmark

Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

September 27, 2016, 11:25 AM - 11:40 AM EDT — New York, NY

Martin Oft, M.D., Vice President of Pre-Clinical and Clinical Development: Anti-tumor activity and immune correlates of PEGylated human IL-10 (AM0010) alone or in combination with anti-PD-1

BioScience Forum

June 22, 2016, 6:00 PM - 9:00 PM PDT — South San Francisco, CA

Peter Van Vlasselaer, Ph.D., Founder, President and CEO: Developing Therapeutic Cytokines to Fight Cancer

American Society of Clinical Oncology (ASCO) Annual Meeting

June 5, 2016, 8:00 AM - 11:30 AM CDT — Chicago, IL

Aung Naing, M.D., Associate Professor, Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center: Clinical activity and safety of PEGylated human IL-10 (AM0010) in combination with anti-PD1
Kyriakos Papadopoulos, M.D., Senior Clinical Investigator at START Center for Cancer Care: Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with pancreatic or colorectal cancer
Details

AACR Annual Meeting

April 19, 2016, 10:30 AM - 12:15 PM EDT — New Orleans, LA

Jeffrey Infante, M.D., Director, Drug Development Program and Principal Investigator, Sarah Cannon Research Institute: Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with advanced solid tumors

Jefferies Immuno-Oncology Summit

April 8, 2016, 11:50 AM - 12:15 PM EDT — Boston, MA

Peter Van Vlasselaer, PhD, President and CEO

3rd Immunotherapy of Cancer Conference (ITOC3) – The Cancer Drug Development Forum

March 22, 2016, 12:20 - 12:35 pm Central European Time — Munich, Germany

Martin Oft, MD: Safety, immune activation and anti-tumor efficacy of PEGylated recombinant human IL-10 (AM0010) in patients with advanced solid tumors – a Phase 1 study

Cowen and Company 36th Annual Health Care Conference

March 9, 2016, 9:00 AM - 9:25 AM EST — Boston, MA

Peter Van Vlasselaer, PhD, President and CEO

Leerink Partners 5th Annual Global Healthcare Conference

February 11, 2016, 1:25 PM - 1:45 PM EST — New York, NY

Peter Van Vlasselaer, PhD, President and CEO

A live audio webcast of the presentation can be accessed at http://wsw.com/webcast/leerink26/armo. A replay will be available for 14 days following the presentation.

34th Annual J.P. Morgan HealthCare Conference

January 12, 2016, 3:00 PM - 3:25 PM PST — San Francisco, CA

Peter Van Vlasselaer, PhD, President and CEO